Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) CEO Sells $15,684.90 in Stock

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) CEO Vininder Singh sold 10,670 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $1.47, for a total value of $15,684.90. Following the completion of the sale, the chief executive officer now owns 2,504,197 shares in the company, valued at $3,681,169.59. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Vininder Singh also recently made the following trade(s):

• On Friday, July 5th, Vininder Singh sold 7,095 shares of Bullfrog AI stock. The shares were sold at an average price of $1.58, for a total value of $11,210.10.

Bullfrog AI Stock Performance

Shares of NASDAQ BFRG opened at $2.20 on Friday. Bullfrog AI Holdings, Inc. has a 52-week low of $1.43 and a 52-week high of $8.35. The business has a fifty day moving average of $2.46 and a two-hundred day moving average of $3.34. The stock has a market cap of $17.27 million, a PE ratio of -2.50 and a beta of 0.11.

Bullfrog AI (NASDAQ:BFRG) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.26) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bullfrog AI stock. Fortem Financial Group LLC bought a new position in shares of Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 53,300 shares of the company’s stock, valued at approximately $171,000. Fortem Financial Group LLC owned about 0.68% of Bullfrog AI as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 0.96% of the company’s stock.

Bullfrog AI Company Profile

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.